Laursen, Peter N
Novo Nordisk (Denmark)
2 papers on CoChatORCID 0000-0002-3905-292X
Most cited papers
- Verified
Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial
Knop, F. K., Aroda, V. R., do Vale, R. D., Holst-Hansen, T., Laursen, P. N., Rosenstock, J., Rubino, D. M., & Garvey, W. T. (2023) · The Lancet
Pharmacology and Obesity TreatmentDiabetes Treatment and Management
Cited by 431
- Verified
Effect of semaglutide 2.4 mg once weekly on 10‐year type 2 diabetes risk in adults with overweight or obesity
Wilkinson, L., Holst‐Hansen, T., Laursen, P. N., Rinnov, A. R., Batterham, R. L., & Garvey, W. T. (2023) · Obesity
Diabetes Treatment and ManagementPharmacology and Obesity Treatment
Cited by 25
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free